Premarket Biotech Digest – $SNGX receives funding, $ISRG board approves split, $SHPG receives Canadian approval

By |August 14th, 2017|Digest|

Achieve Life Sciences Inc. (NASDAQ:ACHV) stock perked up as the company announced received the FDA approval for its IND seeking approval to start U.S. clinical trials assessing smoking cessation drug cytosine. The company has already completed two large-scale Phase 3 studies, TASC and CASCAID, [...]

Premarket Biotech Digest – $SGMO announces strong quarterly numbers, $APEN receives FDA alert, $CELG modifies collaboration

By |August 11th, 2017|Digest|

Sangamo Therapeutics ($SGMO) shot up as the company announced better than expected quarterly numbers. For the second quarter ended June 30, 2017, the company reported a consolidated net loss of $12.5 million, or $0.17 per share, compared to a net loss of $26.6 million, [...]

The Medicines Company stock set to benefit from strong quarterly numbers $MDCO

By |August 10th, 2017|Monthly Investment Ideas|

The Medicines Company ($MDCO) stock showed positive reaction to its second quarter earnings announcement. The company reported its global revenue for the quarter at $18.7 million. The revenue figure included $10.7 million as aggregate revenue from Angiomax. Minocin and Orbactive recorded aggregate sales of $8.0 million in the second quarter [...]

Premarket Biotech Digest – $CLRB reports positive results, $TNDM receives new patent, $DERM inks new deal

By |August 9th, 2017|Digest|

Anthera Pharmaceuticals ($ANTH) stock shot up as the company announced that the FDA has designated its blisibimod an Orphan Drug for the treatment of immunoglobulin A nephropathy. The condition is also known as Berger's disease and is a disorder in which IgA builds up [...]

Aclaris files Marketing Authorization Application in EU, creating a new stock catalyst $ACRS

By |August 8th, 2017|Monthly Investment Ideas|

Aclaris Therapeutics ($ACRS) stock presents a strong investment opportunity as the company is awaiting the FDA approval for its Seborrheic Keratosis treatment. Its lead drug candidate A-101 is a strong contender to become the first FDA approved treatment for the condition. The company has already received a Notice of Allowance [...]

Premarket Biotech Digest – $TEVA gets FDA approval, $IMMY under investigation, $FOLD reports quarterly numbers

By |August 7th, 2017|Digest|

Athersys ($ATHX) announced that the European Medicine Agency has decided that the design of its Phase 3 clinical trial, MASTERS-2, assessing its MultiStem cell therapy product in patients with ischemic stroke should be sufficient to support approval. The decision is in line with with [...]

Premarket Biotech Digest – $LLY announces +ve results, $VTVT receives new patent, $ACRS files marketing application

By |August 4th, 2017|Digest|

Eli Lilly ($LLY) announced results from a second Phase 3 clinical trial assessing its lasmiditan for the acute treatment of migraine, which met its primary endpoint. The results were consistent with the first Phase 3, SAMURAI, reported about a year ago. At two hours [...]

Ultragenyx Pharmaceuticals stock to benefit from better than expected quarterly numbers $RARE

By |August 3rd, 2017|Monthly Investment Ideas|

Ultragenyx Pharmaceuticals Inc. ($RARE) announced its better than expected quarterly results, providing a further fillip to its stock price. The stock is currently nearly 30 percent below its 52 weeks high of $91.35 and is in recovery mode. The positive quarterly earnings and its robust pipeline are expected to fuel [...]

Premarket Biotech Digest – $VRTX gets FDA approval, $EYEG starts enrollment, $SGEN announces new deal

By |August 2nd, 2017|Digest|

AstraZeneca ($AZN) reported receiving Breakthrough Therapy designation for its acalabrutinib for treating patients with mantle cell lymphoma who have received at least one prior line of therapy. The therapy is currently in a Phase 2 clinical trial. it is an orally available second generation [...]

Neurocrine Biosciences a strong buy ahead of earnings announcement $NBIX

By |August 1st, 2017|Monthly Investment Ideas|

Neurocrine Biosciences Inc. ($NBIX) is set to announce its second quarter earnings on August 3rd. The company is expected to provide update about its recently approved Ingrezza capsules. This is the first FDA approved therapy for treating Tardive Dyskinsia (TD). The company had reported a net loss of $0.90 per [...]

Premarket Biotech Digest – $GILD receives EU approval, $IVC changes production site, $CYTR inks new deal

By |July 31st, 2017|Digest|

Dynavax Techologies ($DVAX) stock perked up as the company announced that an FDA advisory panel voted 12-1 in favor of the available data for is hepatitis B vaccine for adults. The advisory panel is of the view that the data supports the safety profile [...]

Premarket Biotech Digest – $CERS inks new deal, $IDXG reports CIGNA coverage, $AZN announces negative results

By |July 28th, 2017|Digest|

Cerus Corporation ($CERS) stock perked up as the company announced inking deal with the Central California Blood Center. The new deal pertains to the company’s INTERCEPT plasma. The Center will use the plasma for manufacturing pathogen-reduced cryoprecipitate, to control bleeding in patients with acquired [...]

Rigel Pharmaceuticals looks strong ahead of FDA decision for Tavalisse

By |July 27th, 2017|Monthly Investment Ideas|

Rigel Pharmaceuticals Inc. ($RIGL) stock is currently trading over 43 percent lower than its 52 weeks high of $4.38, showing a steep upside potential ahead. The company stock is likely to get boost from its progress on fostamatinib, an oral spleen tyrosine kinase inhibitor, for the treatment of patients with [...]

Premarket Biotech Digest – $GALT receives new patent, $CYRX inks new deal, $CGNT announces acquisition,

By |July 26th, 2017|Digest|

Gelectin Therapeutics ($GALT) stock shot up as the company announced receiving a notice of allowance from the USPTO for a patent covering method of use of lead product candidate GR-MD-02 as a means to enhance anti-tumor activity and increase survival effects of combining GR-MD-02 [...]

Enanta stock to gain from upcoming FDA decision for HCV drug $ENTA

By |July 25th, 2017|Monthly Investment Ideas|

Enanta Pharmaceuticals ($ENTA) focuses on developing therapies for liver conditions. The company has a strong Hepatitis C virus (HCV) portfolio, which it continually expands. Apart from HCV, the company also focuses on other liver related ailments such as Respiratory Syncytial Virus infection (RSV) and Non-alcoholic Steatohepatitis (NASH). However, the upcoming [...]

Premarket Biotech Digest – $BCLI receives new funding, $MNTA receives mixed ruling on litigation, $HCA inks new deal

By |July 24th, 2017|Digest|

Brainstorm Cell Therapeutics ($BCLI) announced that it has been awarded $16 million by the California Institute for Regenerative Medicine. The funds will be used for support the company’s pivotal Phase 3 clinical trial assessing NurOwn for the treatment of amyotrophic lateral sclerosis. The primary [...]

Premarket Biotech Digest – $BVXV reports positive data, $AMGN receives FDA acceptance, $KANG inks new agreements

By |July 21st, 2017|Digest|

Diffusion Pharmaceutics ($DFFN) stock reacted positively to the news of the company achieving drug production milestone for its planned Phase 3 trial. The company completed a major production run of its lead drug candidate trans sodium crocetinate (TSC). The produced quantity is sufficient to [...]

Kamada stock set to recover from EMA withdrawal shock, presents good investment opportunity $KMDA

By |July 20th, 2017|Monthly Investment Ideas|

Kamada Ltd. ($KMDA) stock showed strong performance as it gained over 42 percent in the past 12 months. However, the actual performance of the stock was overshadowed by a steep decline of 25 percent in the past one month. The decline was mainly due to the company’s withdrawal of European [...]

Premarket Biotech Digest – $TTOO gets CE Mark, $QURE receives new patent, $GILD receives FDA approval

By |July 19th, 2017|Digest|

Vertex Pharmaceuticals ($VRTX) reported positive mid-stage results from three different triple combination regimens in cystic fibrosis (CF) patients suffering from one F508del mutation and one minimal function mutation. The data from the Phase 2 study showed mean absolute improvements in lung function of 9.7% [...]

Valeant sells off business unit to reduce debt pile, pushing stock higher $VRX

By |July 18th, 2017|Monthly Investment Ideas|

Valeant Pharmaceuticals International Inc. ($VRX) stock gained over 19 percent this year so far. After a prolonged period of downward spiral, the stock is showing signs of revival. The change is mainly on account of the company taking strategic decision to boost its core business and trim its debt pile. [...]

s2Member®